Emboline Secures $20M to Launch Stroke-Reducing Heart Device

SANTA CRUZ, CA – March 11, 2026 – Medical technology firm Emboline, Inc. has secured $20 million in growth capital from Trinity Capital Inc., a move designed to propel its innovative stroke-prevention device from the clinical trial stage to commercial reality. The funding comes at a critical juncture for the company as it prepares to unveil pivotal clinical trial data for its Emboliner® Embolic Protection System later this month.

The investment will fuel Emboline's preparations for a commercial launch in the United States and Europe, targeting a market grappling with one of the most feared complications of structural heart procedures: stroke.

A Pivotal Moment for Commercialization

This financing represents a significant vote of confidence in Emboline's technology and its potential to address a persistent clinical challenge. Trinity Capital, an asset manager with a growing life sciences portfolio, is providing the capital needed to transition Emboline from a development-stage company to a commercial entity.

"We are excited to partner with Trinity Capital at a pivotal moment for Emboline," said Scott Russell, President and CEO of Emboline, in a statement. "With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the United States and Europe later this year."

The funds are earmarked for scaling up manufacturing, expanding the corporate team, and navigating the final regulatory hurdles required to bring the Emboliner® system to physicians and their patients. For Trinity Capital, the investment aligns with its strategy of backing growth-stage companies with disruptive technologies.

"Emboline's embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence when performing complex structural heart procedures while helping reduce the risk of stroke and other embolic complications," stated Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "We are pleased to support Emboline during this important stage as the company prepares to bring its technology to physicians and patients worldwide."

The Race to Reduce Stroke Risk in TAVR

Transcatheter Aortic Valve Replacement (TAVR) has revolutionized cardiology, offering a minimally invasive alternative to open-heart surgery for patients with aortic stenosis. However, the procedure is not without risk. Stroke remains a significant concern, with an incidence rate between 1.5% and 2.5% in the 30 days following a TAVR procedure. While that number may seem small, it represents a life-altering event for thousands of patients each year.

Research has shown that the true scope of embolic events is much larger. Imaging studies reveal that nearly 100% of TAVR patients have embolic debris—tiny particles of calcium or tissue dislodged during the procedure—travel to the brain. While most of these do not result in a clinically apparent stroke, they are linked to cognitive decline and other neurological issues.

This is the problem Emboline aims to solve. The Emboliner® system is designed to provide what the company describes as "full cerebral and systemic embolic protection." Unlike some existing devices that only offer partial cerebral protection, the Emboliner® features a unique filter designed to capture and remove debris from the bloodstream before it can travel to the brain or other vital organs.

High-Stakes Clinical Trial Nears Revelation

The timing of the funding is closely tied to the imminent release of data from the PROTECT H2H clinical trial. Emboline recently completed enrollment for this 500-patient study, which is notable for its ambitious head-to-head design. The trial directly compares the safety and efficacy of the Emboliner® system against the current market leader, Boston Scientific’s Sentinel™ Cerebral Protection System.

This direct comparison is a bold strategic move. The study is designed to assess not only major adverse events and stroke rates but also the total amount of embolic debris captured by each device. Success in this trial could provide Emboline with powerful evidence to argue for the superiority of its system.

The medical community will not have to wait long for the results. Emboline is scheduled to present the findings in a Late-Breaking Clinical Trial session at the American College of Cardiology (ACC) Annual Scientific Session in New Orleans on March 29, 2026. A positive outcome would significantly bolster the company's case with regulators and clinicians ahead of its planned commercial launch.

Navigating a Crowded and Complex Market

Emboline is entering a competitive and challenging market. The TAVR embolic protection space, valued at over $100 million and projected to grow rapidly, is currently dominated by Boston Scientific's Sentinel® device. The Sentinel®, which received FDA clearance in 2017, uses two filters to protect two of the three major arteries supplying blood to the brain.

However, the clinical evidence for the Sentinel® has been mixed. Major randomized trials, including PROTECTED TAVR and the European BHF PROTECT-TAVI, failed to show that routine use of the device significantly reduced the overall rate of periprocedural stroke, its primary endpoint. While a secondary analysis of one trial suggested a reduction in more severe, disabling strokes, the overall results have left the door open for a competitor with more definitive data.

Other devices, such as Keystone Heart's TriGUARD 3™, have also entered the market in Europe but have faced their own challenges in clinical trials and have not yet secured FDA approval. This landscape creates both a high bar for entry and a clear opportunity for a device that can unequivocally demonstrate a meaningful reduction in stroke risk.

Expert Perspectives and the Future of Heart Safety

Among interventional cardiologists, the use of embolic protection devices (EPDs) remains a topic of debate. Many physicians, seeing the visible debris captured in filters, are convinced of their value and use them in nearly every TAVR case. They argue that preventing any amount of debris from reaching the brain is a worthwhile goal.

Others, however, point to the results of large clinical trials and question the routine use of EPDs for all patients, especially given their additional cost. They argue that until a device can definitively prove it reduces the overall rate of clinical stroke, its use should be reserved for patients at the highest risk.

Emboline’s upcoming data could be a turning point in this debate. If the PROTECT H2H trial demonstrates that the Emboliner® is not only safe but also superior to the current standard in reducing stroke or capturing debris, it could transform the standard of care. Such a result would provide physicians with the compelling evidence they have been seeking and could accelerate the adoption of embolic protection as a routine part of every TAVR procedure.

With fresh capital and crucial clinical data on the horizon, Emboline stands at the threshold of potentially reshaping patient safety in structural heart medicine. All eyes in the cardiology world will be on New Orleans at the end of the month to see if the Emboliner® can deliver on its promise.